SABINA INTERNATIONAL

Study identifier:D589SR00002

ClinicalTrials.gov identifier:NCT03857178

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-country study on the Prescription Patterns of Short Acting Beta-2 Agonist (SABA) and its potential effects on asthma control: A Cross-Sectional Study on SABA use in Asthma

Medical condition

asthma

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

8617

Study type

Observational

Age

N/A

Date

Study Start Date: 29 Mar 2019

Primary Completion Date: 06 May 2020

Study Completion Date: 06 May 2020

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2021 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

San Salvador, Argentina

Arms	Assigned Interventions

Documents available

This is the CSR of the study.
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com